NCT05291780 - Stereotactic Ablative Radiotherapy in Locally Advanced Non Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Locally Advanced Lung Non-Small Cell Carcinoma

Interventions

RADIATION

Stereotactic Ablative Radiotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be of at least 35-40 Gy in 5 fractions. The dose of SABR will be increased, case by case, respecting the maximum tolerance dose of the healthy structures.~Participants will SABR once a day for 5 days, Monday through Friday (around 1 week)."

Trial Locations (1)

05100

"Radiotherapy Oncology Centre S.Maria Hospital", Terni

All Listed Sponsors

collaborator

Paola Anselmo,MD

UNKNOWN

collaborator

Michelina Casale,PhD

UNKNOWN

collaborator

Ernesto Maranzano,MD

UNKNOWN

collaborator

Fabio Trippa,MD

UNKNOWN

lead

"Radiotherapy Oncology Centre Santa Maria Hospital"

OTHER